283 related articles for article (PubMed ID: 33031542)
1. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
Davis JE; Handunnetti SM; Ludford-Menting M; Sharpe C; Blombery P; Anderson MA; Roberts AW; Seymour JF; Tam CS; Ritchie DS; Koldej RM
Blood Adv; 2020 Oct; 4(19):4849-4859. PubMed ID: 33031542
[TBL] [Abstract][Full Text] [Related]
2. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract][Full Text] [Related]
6. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
Verma A; Mbughuni M; Mariash E; Mesa H
J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
[No Abstract] [Full Text] [Related]
7. Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
Grieve C; Joseph A; Drullinsky P; Zelenetz AD; Hamlin P; Kumar A
Leuk Lymphoma; 2024 Feb; 65(2):235-241. PubMed ID: 38264906
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Zhou X; Steinhardt MJ; Düll J; Krummenast F; Danhof S; Meckel K; Nickel K; Grathwohl D; Leicht HB; Rosenwald A; Einsele H; Rasche L; Kortüm M
Eur J Haematol; 2020 Apr; 104(4):352-355. PubMed ID: 31922303
[TBL] [Abstract][Full Text] [Related]
9. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
Agarwal R; Chan YC; Tam CS; Hunter T; Vassiliadis D; Teh CE; Thijssen R; Yeh P; Wong SQ; Ftouni S; Lam EYN; Anderson MA; Pott C; Gilan O; Bell CC; Knezevic K; Blombery P; Rayeroux K; Zordan A; Li J; Huang DCS; Wall M; Seymour JF; Gray DHD; Roberts AW; Dawson MA; Dawson SJ
Nat Med; 2019 Jan; 25(1):119-129. PubMed ID: 30455436
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Portell CA; Wages NA; Kahl BS; Budde LE; Chen RW; Cohen JB; Varhegyi NE; Petroni GR; Williams ME
Blood Adv; 2022 Mar; 6(5):1490-1498. PubMed ID: 34700344
[TBL] [Abstract][Full Text] [Related]
11. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
13. Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
Leitinger EJ; Wright RM; Nelson N; Anderson MA; Juneja S
Pathology; 2021 Dec; 53(7):926-929. PubMed ID: 33947523
[No Abstract] [Full Text] [Related]
14. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Roulin L; Haioun C; Lemonnier F
Ann Hematol; 2021 May; 100(5):1345-1347. PubMed ID: 33655374
[No Abstract] [Full Text] [Related]
15. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
16. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
Agarwal R; Dawson MA; Dreyling M; Tam CS
Leuk Lymphoma; 2018 Dec; 59(12):2769-2781. PubMed ID: 29912596
[TBL] [Abstract][Full Text] [Related]
17. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Svanberg R; Ostrowski SR; Nasserinejad K; Kersting S; Dobber JA; Mattson M; Tran HTT; Levin MD; Mous R; Kater AP; Niemann CU
Leuk Lymphoma; 2020 Dec; 61(14):3422-3431. PubMed ID: 32865439
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
19. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
20. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
